Johnson & Johnson
General ticker "JNJ" information:
- Sector: Health Care
- Industry: Drug Manufacturers - General
- Capitalization: $395.7B (TTM average)
Johnson & Johnson follows the US Stock Market performance with the rate: 38.5%.
Estimated limits based on current volatility of 1.1%: low 232.16$, high 237.10$
Factors to consider:
- Company included in S&P500 list
- Company pays dividends (quarterly): last record date 2026-02-24, amount 1.30$ (Y2.22%)
- Total employees count: 139800 as of 2024
- Top business risk factors: Geopolitical risks, Litigation risks, Product liability, Intellectual property risks, Supply chain disruptions
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-28 to 2027-12-28
- 2025-12-28 to 2026-12-28 estimated range: [166.31$, 228.51$]
- 2026-12-28 to 2027-12-28 estimated range: [181.76$, 246.77$]
Financial Metrics affecting the JNJ estimates:
- Negative: with PPE of 19.3 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 27.17 > 18.52
- Positive: 19.49 < Shareholder equity ratio, % of 40.93 <= 42.60
- Positive: Industry earnings per price (median), % of 5.99 > 4.54
- Positive: 5.46 < Industry operating cash flow per share per price (median), % of 6.53
- Positive: 0.07 < Operating cash flow per share per price, % of 4.84
- Positive: Industry operating profit margin (median), % of 26.73 > 9.67
- Negative: Investing cash flow per share per price, % of -4.65 <= -4.45
- Positive: Return on assets ratio (scaled to [-100,100]) of 11.86 > 6.12
Short-term JNJ quotes
Relationship graph
Long-term JNJ plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-29 | 2025-12-28 |
|---|---|---|---|
| Operating Revenue | $85,159.00MM | $88,821.00MM | $94,193.00MM |
| Operating Expenses | $61,750.00MM | $66,672.00MM | $68,597.00MM |
| Operating Income | $23,409.00MM | $22,149.00MM | $25,596.00MM |
| Non-Operating Income | $-8,347.00MM | $-5,462.00MM | $6,985.00MM |
| Interest Expense | $772.00MM | $755.00MM | $971.00MM |
| R&D Expense | $15,085.00MM | $17,232.00MM | $14,665.00MM |
| Income(Loss) | $15,062.00MM | $16,687.00MM | $32,581.00MM |
| Taxes | $1,736.00MM | $2,621.00MM | $5,777.00MM |
| Other Income(Loss) | $21,827.00MM | $0.00MM | $0.00MM |
| Profit(Loss)* | $56,980.00MM | $14,066.00MM | $26,804.00MM |
| Stockholders Equity | $68,774.00MM | $71,490.00MM | $81,544.00MM |
| Inventory | $11,181.00MM | $12,444.00MM | $14,191.00MM |
| Assets | $167,558.00MM | $180,104.00MM | $199,210.00MM |
| Operating Cash Flow | $22,791.00MM | $24,266.00MM | $24,530.00MM |
| Capital expenditure | $4,543.00MM | $4,424.00MM | $4,832.00MM |
| Investing Cash Flow | $878.00MM | $-18,599.00MM | $-23,588.00MM |
| Financing Cash Flow | $-15,825.00MM | $-3,132.00MM | $-5,539.00MM |
| Earnings Per Share** | $22.49 | $5.84 | $11.04 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.